Septerna
Septerna's revenue rose 4174.5% to $46 million in fiscal 2025. Its operating margin was −148.6%, up from −7,518.4% a year earlier. Free cash flow was $110 million. The diluted share count rose 347.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Septerna does
Septerna is a clinical-stage biotechnology company that discovers oral small-molecule drugs aimed at GPCRs. These are proteins in cell membranes that detect signals and relay them into the cell. They affect nearly every organ system, and many approved drugs already target them. Septerna says many possible GPCR targets have not yet been tapped for drugs.
The company has no approved products and does not sell any. Its method is its proprietary Native Complex Platform, which reproduces GPCRs outside cells in their natural shape so researchers can study them and find molecules that bind to them. Its own programs focus first on endocrinology, immunology and inflammation, and metabolic diseases. Its lead programs include an oral drug candidate, SEP-479, for hypoparathyroidism, a condition of low parathyroid hormone, and a candidate called SEP-631.
Its income comes from partners rather than from sales. In May 2025 it signed a collaboration and license agreement with Novo Nordisk on metabolic disease targets. Novo paid an upfront fee in July 2025, and Septerna can receive milestone payments and other payments if programs advance. Septerna keeps all other rights to its platform and programs.
Its biggest risks, as it describes them
- A short operating history and large losses, which it expects to continue.
- Needing substantial additional funding to run its business.
- Being early in development, with no advanced clinical trials completed, so a product may be years away or never come.
- Clinical trials that may be delayed or fail to show safety and effectiveness.
- Reliance on outside manufacturers, research organizations and suppliers.
Income statement
Septerna lost money in fiscal 2025: a net loss of $49 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 88 | 351 | 391 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | — | — | — |
| Current ratio | 16.3x | 27.8x | 4.7x |
| Quick ratio | 16.3x | 27.8x | 4.7x |
Cash flow
Projections
Project Septerna's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Septerna reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | −5,860.0% | 4,413.2% |
| Altman Z'' | 14.99 | 3.75 |
| Accruals ratio | −1.5% | −30.2% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Pass |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | Pass |
| F-score | — | — |
Compare
Put Septerna side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Septerna | FY25 | 4,174.5% | −148.6% | 238.7% | — | — | — | |
| Protagonist Therapeutics | FY25 | −89.4% | −343.6% | 121.9% | — | — | — | Compare |
| Wave Life Sciences | FY25 | −60.5% | −504.1% | −440.5% | — | — | — | Compare |
| Editas Medicine | FY25 | 25.4% | −394.9% | −409.3% | — | — | 2 | Compare |
| Kymera Therapeutics | FY25 | −16.7% | −891.1% | −597.6% | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 0 | 1 | 46 |
| Revenue growth | — | 611.9% | 4,174.5% |
| Gross profit | — | — | — |
| Research and development | 36 | 65 | 98 |
| Operating income | 2 | −81 | −68 |
| Net income | 4 | −72 | −49 |
| Diluted EPS (US$) | 0.29 | −7.26 | −1.10 |
| Diluted shares (millions) | 2 | 10 | 44 |
| Cash flow | |||
| Cash from operations | −39 | −68 | 110 |
| Capital expenditure | 3 | 2 | 0 |
| Free cash flow | −42 | −70 | 110 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 2 | 3 | 8 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 88 | 351 | 391 |
| Debt incl. finance leases | — | — | — |
| Total assets | 131 | 457 | 596 |
| Total liabilities | 20 | 36 | 214 |
| Shareholders' equity | −38 | 420 | 382 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | 1,374.2% | −7,518.4% | −148.6% |
| Net margin | 2,768.2% | −6,678.9% | −106.4% |
| Free cash flow margin | −27,550.3% | −6,471.9% | 238.7% |
| Rule of 40 (growth + FCF margin) | — | −5,860.0% | 4,413.2% |
| Return on capital | — | — | — |
| Return on equity | — | −37.6% | −12.2% |
| Return on assets | — | −24.4% | −9.3% |
| Net debt to EBITDA | — | — | — |